These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
872 related items for PubMed ID: 31492651
1. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators. Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651 [Abstract] [Full Text] [Related]
15. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA, Ozanimod Study Investigators. Eur J Neurol; 2021 Nov 19; 28(11):3722-3730. PubMed ID: 34292643 [Abstract] [Full Text] [Related]
16. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, ADVANCE Study Investigators. Lancet Neurol; 2014 Jul 19; 13(7):657-65. PubMed ID: 24794721 [Abstract] [Full Text] [Related]
17. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A, Tolebrutinib Phase 2b Study Group. Lancet Neurol; 2021 Sep 19; 20(9):729-738. PubMed ID: 34418400 [Abstract] [Full Text] [Related]
18. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II investigators. Lancet; 2012 Nov 24; 380(9856):1829-39. PubMed ID: 23122650 [Abstract] [Full Text] [Related]
19. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators. Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652 [Abstract] [Full Text] [Related]
20. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Zhang J, Shi S, Zhang Y, Luo J, Xiao Y, Meng L, Yang X. Cochrane Database Syst Rev; 2017 Nov 27; 11(11):CD010968. PubMed ID: 29178444 [Abstract] [Full Text] [Related] Page: [Next] [New Search]